title: Folliculitis-perifolliculitis related to erlotinib therapy spares previously irradiated skin.
abstract: Erlotinib, a specific epidermal growth factor receptor tyrosine kinase inhibitor, is used to treat various metastatic cancers. It is known to cause an acneiform rash. Herein, we report a case where the rash spared the previous radiotherapy field. A limitation of this study is that it is an anecdotal case report. Further research into the pathologic process of the rash is warranted to understand the reason for its absence in the irradiated skin.
authors.affiliation: Department of Clinical Oncology, St James's Institute of Oncology, Leeds, United Kingdom.
authors.forename: Jayati
authors.initials: J
authors.lastname: Acharya
authors.forename: Calum
authors.initials: C
authors.lastname: Lyon
authors.forename: David M
authors.initials: DM
authors.lastname: Bottomley
mesh_terms: D000328:Adult; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000532:radiotherapy; D000069347:Erlotinib Hydrochloride; D005499:Folliculitis / Q000139:chemically induced*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D008297:Male; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011799:Quinazolines / Q000009:adverse effects*; D012867:Skin / Q000528:radiation effects*
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride